Egy-score predicts severe hepatic fibrosis and cirrhosis in egyptians with chronic liver diseases: A pilot study

Mohamed A. Alboraie, Mahmoud E. Afifi, Fathy G. Elghamry, Helmy A. Shalaby, Gamal E. Elshennawy, Ahmed A. Abdelaziz, Mohamed U. Shaheen, Amany R.A. Abo El-Seoud

Research output: Contribution to journalJournal articlepeer-review

4 Scopus citations

Abstract

Background: Non-invasive methods for assessment of hepatic fibrosis are increasingly needed. Recent studies showed that combined elevation of tumor markers CA 19-9 and CA 125 is predictive of severe hepatic fibrosis or cirrhosis with high specificity. Objectives: We aimed at developing a new panel of surrogate biomarkers for prediction of the stage of hepatic fibrosis by combining tumor markers with other known biomarkers of hepatic fibrosis. Patients and Methods: A total of 92 patients with different types of chronic liver diseases (chronic hepatitis B, chronic hepatitis C and autoimmune hepatitis), were prospectively enrolled in our cohort. They were subjected to: ALT, AST, GGT, ALP, total bilirubin, INR, total cholesterol, albumin, platelet count, cancer antigen 19-9 (CA 19-9), cancer antigen 125 (CA 125), cancer antigen 15-3 (CA 15-3), haptoglobin, alpha-2-macroglobulin, apolipoprotein A1, abdominal ultrasound, liver biopsy and histological staging of hepatic fibrosis using the METAVIR system. Results: Combined elevation of CA 19-9 and CA 125 with a summated value > 37 U/mL is predictive of severe hepatic fibrosis or cirrhosis (stage F3-F4 METAVIR) with a probability of 77.6%. Multivariate analysis showed that the most relevant collection of biomarkers for prediction of stage of hepatic fibrosis is: CA 19-9, age, alpha-2- macroglobulin, total bilirubin, platelet count & albumin. We developed a new score, named the “Egy-Score”, using a regression equation composed of this panel of biomarkers. Egy-Score could differentiate no or early fibrosis (stage F0-F2 METAVIR) from severe fibrosis or cirrhosis (stage F3-F4 METAVIR) with 83.7% accuracy. Conclusions: Non-invasive assessment of hepatic fibrosis could be done using the Egy-Score. Egy-Score could differentiate no or early fibrosis (stage F0-F2 METAVIR) from severe fibrosis or cirrhosis (stage F3 - F4 METAVIR) with 83.7% accuracy.

Original languageEnglish
Article numbere10810
Pages (from-to)1-8
Number of pages8
JournalHepatitis Monthly
Volume13
Issue number6
DOIs
StatePublished - Jun 2013
Externally publishedYes

Keywords

  • Alpha-Macroglobulins
  • Biological markers
  • CA-19-9 antigen
  • Fibrosis
  • Liver cirrhosis

Fingerprint

Dive into the research topics of 'Egy-score predicts severe hepatic fibrosis and cirrhosis in egyptians with chronic liver diseases: A pilot study'. Together they form a unique fingerprint.

Cite this